Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

O Hermine1, Th Maciel1, I Moura1

  • 1Département d'hématologie, Centre National de référence des mastocytoses et Institut Imagine, Paris Descartes university, Hôpital Necker, 149 Rue de Sèvres, 75015 Paris.

Nephrologie & Therapeutique
|February 22, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and outcomes of patients with pediatric-onset non-mastocytosis mast cell activation disorders: A CEREMAST study.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Ibrutinib-induced spontaneous penile hematoma.

Annales de dermatologie et de venereologie·2025
Same author

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

The journal of allergy and clinical immunology. In practice·2025
Same author

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma.

Allergy·2024
Same author

Correction to: Cost-Effectiveness Evaluation of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2022
Same journal

Supporting patients and family members facing treatment choices in chronic kidney disease: What do professionals think of the decision aids used? - Professionals’ views on treatment decision support tools

Nephrologie & therapeutique·2026
Same journal

From Turing to ChatGPT: The origins and transformations of medical artificial intelligence

Nephrologie & therapeutique·2026
Same journal

Analysis of the predictive value of serum Cys-C and IL-6 levels for acute kidney injury in patients with acute respiratory distress syndrome.

Nephrologie & therapeutique·2026
Same journal

Navigating pain in chronic kidney disease: Overcoming inertia!

Nephrologie & therapeutique·2026
Same journal

Kidney health for all: caring for people, protecting the planet1.

Nephrologie & therapeutique·2026
Same journal

When the heart breaks, the kidneys follow: A case of Takotsubo syndrome

Nephrologie & therapeutique·2026
See all related articles

Erythropoietin (EPO) is crucial for red blood cell production. In chronic kidney disease anemia, new therapeutic targets like Hypoxia Inducible Factor (HIF) and GDF-11 are being explored alongside EPO treatment.

Area of Science:

  • Hematology
  • Nephrology
  • Molecular Biology

Background:

  • Erythropoietin (EPO) regulates erythropoiesis, influenced by Hypoxia Inducible Factor (HIF) and oxygen levels.
  • Anemia in chronic renal failure stems from EPO deficiency, iron deficiency, and inflammation.
  • Emerging research suggests GDF-11 may also contribute to anemia in chronic kidney disease.

Purpose of the Study:

  • To explore the role of EPO, HIF, and GDF-11 in anemia associated with chronic kidney disease.
  • To identify potential new therapeutic targets for managing anemia in renal failure.

Main Methods:

  • Review of existing literature on erythropoiesis regulation.
  • Analysis of factors contributing to anemia in chronic kidney disease.
  • Hypothesis generation regarding novel therapeutic targets.
Keywords:
Anemia ErythropoiesisAnémieCKDGD-11HIFIRCRécepteur à la transferrineTransferrin receptorÉrythropoïèse

Related Experiment Videos

Main Results:

  • EPO deficiency is a primary driver of anemia in chronic kidney disease.
  • HIF protein stability is oxygen-dependent and influences EPO production.
  • GDF-11 is a recently hypothesized factor potentially involved in this condition.

Conclusions:

  • EPO treatment remains a standard therapy for anemia of chronic kidney disease.
  • HIF and GDF-11 represent promising novel therapeutic targets.
  • Integrated therapeutic strategies targeting EPO, HIF, and GDF-11 may improve anemia management.